For U.S. Healthcare Professionals

Questions? Call 855-4ADYNOVATE

Stay Updated

Resources & Downloads

Unique resources to enrich discussions with your patients

Product Reimbursement Support

Find common billing and prescribing forms right here, for your office's convenience.

Patient Resources

Download the appropriate resources to share with your patients to help them set goals and track their progress. Sign up to receive notifications when new materials are added.

  • Setting Goals Worksheet

    Use this worksheet to determine appropriate goals for your patients and get them started striving toward a goal of zero bleeds.

    Download Setting Goals Worksheet
  • Bleed Assessment Worksheet

    Provide the Bleed Assessment Worksheet to patients to help them stay on top of their ABR plan.

    Download Bleed Assessment Worksheet
  • ABR Worksheet

    Guide your patients toward tracking their ABR progress when they set goals and follow their treatment plan.

    Download ABR Worksheet
  • Infusion Log

    Share the Infusion Log sheet so patients can easily keep infusion and vial records all in one place.

    Download Infusion Log
Detailed Important Risk Information
Prescribing Information (PI)
ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated] Important Information
Indications

ADYNOVATE, Antihemophilic Factor (Recombinant), PEGylated, is a human antihemophilic factor indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to reduce the frequency of bleeding episodes

Limitation of Use

ADYNOVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION


Click here for ADYNOVATE full Prescribing Information.



ADVATE [Antihemophilic Factor (Recombinant)] Important Information
Indications

ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • Control and prevention of bleeding episodes.
  • Perioperative management.
  • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes.

ADVATE is not indicated for the treatment of von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

Neutralizing Antibodies
Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

Click here for ADVATE full Prescribing Information.